Eli Lilly is a buy
Eli Lilly’s year-to-date stock performance.
Eli Lilly: “This stock is as hated now as it was loved not that long ago…I think that it is a buy.”
Coinbase’s year-to-date stock performance.
IES’ year-to-date stock performance.
IES: “This is a terrific infrastructure play.”
Semtech’s year-to-date stock performance.
Semtech: “I do think that Semtech is just a traditional kind of semiconductor company. I do prefer Texas Instruments to that one.”
Cameco’s year-to-date stock performance.
Cameco: “It is an incredibly expensive stock versus the rest of the market…I am a ‘ka-ching ka-ching’ when it comes to Cameco.”
Marvell Technology’s year-to-date stock performance.
Apple’s year-to-date stock performance.
Apple: “Apple, own it don’t trade it…I would wait for a dip because the bears are all over it every minute of the day. Keep that in mind, and then pull the trigger.”
Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.
Disclaimer The CNBC Investing Club Charitable Trust holds shares of Eli Lilly and Apple.
Questions for Cramer?
Call Cramer: 1-800-743-CNBC
Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money Twitter – Jim Cramer Twitter – Facebook – Instagram
Questions, comments, suggestions for the “Mad Money” website? madcap@cnbc.com